Translate
About
Akeso Inc (HK:9926) — investor relations, events, news, and company updates on 6ix.
Latest News
Yesterday
Ivonescimab Receives Major Recommendations Across Multiple Therapies in the 2026 CSCO NSCLC Guideline
Apr 21 2026
Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026
Apr 7 2026
Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026
Mar 31 2026
Ivonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026
Mar 27 2026
Akeso Reports Full-Year 2025 Financial Results
Recent Videos
कैसे? CHINESE PHARMA COMPANY MERCK को पीछे छोड़ रही है? akeso biopharma Founder Success Story Hindi?
Apr 14, 2026
Akeso (9926)|US consumer sentiment falls to three-month low as war fans inflation fears|30-03-2026
Mar 30, 2026
Akeso Inc. 2025 annual report
Mar 27, 2026
How to Invest in Akeso Inc (9926.HK) Step by Step
Feb 27, 2026
Financials
Revenue
HK$3.06 B
Market Cap
HK$129.42 B
EPS
-0.96